COMBINED CYTOGENETIC, FISH AND MOLECULAR ANALYSIS IN ACUTE PROMYELOCYTIC LEUKEMIA AT DIAGNOSIS AND IN COMPLETE REMISSION

Citation
M. Mancini et al., COMBINED CYTOGENETIC, FISH AND MOLECULAR ANALYSIS IN ACUTE PROMYELOCYTIC LEUKEMIA AT DIAGNOSIS AND IN COMPLETE REMISSION, British Journal of Haematology, 91(4), 1995, pp. 878-884
Citations number
32
Categorie Soggetti
Hematology
ISSN journal
00071048
Volume
91
Issue
4
Year of publication
1995
Pages
878 - 884
Database
ISI
SICI code
0007-1048(1995)91:4<878:CCFAMA>2.0.ZU;2-E
Abstract
This study reports the results of a simultaneous application of cytoge netic fluorescence in situ hybridization (FISH) and molecular analysis (RT-PCR) in 28 APL cases (23 M3 and live M3v; 26 studied at diagnosis and two at relapse). FISH on metaphases identified the t(15;17) in al l cases who were positive for the PML/RAR alpha transcript by RT-PCR, Conventional cytogenetics revealed the t(15;17) in only 68% of cases. However, it enabled the detection of additional chromosome changes in five cases, three of whom were M3v. 11 patients were also investigated during complete remission (CR) by both FISH and RT-PCR, in order to e valuate residual disease; the duration of CR at the time of analysis r anged between 1 and 16 months, with three patients being studied twice . Comparison of RT-PCR and FISH result showed a very good correlation, In fact, of the 10 samples which were RT-PCR positive for residual di sease, all were also recognized by interphase FISH, and eight were pos itive by metaphase FISH, Of the three samples negative at RT-PCR, all were also negative at the interphase FISH, The results of this study i ndicate that: (a) the t(15;17) is present in all cases positive for th e PML/RAR alpha rearrangement, thus in virtually all true APLs; (b) st andard cytogenetics, capable of unravelling the t(15;17) in only 68% o f cases, enables recognition of additional chromosome changes of poten tial clinical and prognostic significance; (c) FISH on interphase nucl ei is a reliable tool for the monitoring of residual disease, with a s ensitivity greater than that of FISH on metaphase cells and superimpos able to that of RT-PCR.